Dermatomyositis
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 21 trials with date data
Clinical Trials (21)
Total enrollment: 1,486 patients across 21 trials
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Study of NM8074 in Patients with Dermatomyositis (DM)
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
A Study In Adults With Moderate To Severe Dermatomyositis
Study of IFN-K in Dermatomyositis
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
Study of Tofacitinib in Refractory Dermatomyositis
RCT of Tocilizumab for Anti-MDA5+DM
Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.